Conmed (CNMD) Tops Q1 EPS by 3c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
CONMED (CNMD) PT Raised to $95 at Needham & Company
April 25, 2019 8:26 AM EDTNeedham & Company analyst Mike Matson raised the price target on CONMED (NASDAQ: CNMD) to $95.00 (from $94.00) while maintaining a Buy rating.
The analyst commented, " CNMD's 1Q19 revenue and EPS beat consensus. Given the recent Buffalo Filter acquisition, management provided 2019 revenue guidance and also raised its... More
